Market Place
Sourcing Support
Fortress Biotech Unveils 2025 Financials And Key Updates
31 Mar 2026 //
GLOBENEWSWIRE
Fortress Biotech Unveils Q3 2025 Financials & Corporate Updates
14 Nov 2025 //
GLOBENEWSWIRE
Fortress, Urica Dose First Patients In Ph3 Dotinurad Gout Trial
21 Oct 2025 //
GLOBENEWSWIRE
Fortress Biotech And Urica Therapeutics Unveil Crystalys
01 Oct 2025 //
GLOBENEWSWIRE
Fortress Biotech to Present at H.C. Wainwright Global Investment
02 Sep 2025 //
GLOBENEWSWIRE
Fortress Biotech Reports Q2 2025 Financial Results and Highlights
14 Aug 2025 //
GLOBENEWSWIRE
Fortress Biotech Closes Sale of Checkpoint Therapeutics
30 May 2025 //
GLOBENEWSWIRE
Fortress to Join Wainwright Royalty Virtual Conference
07 May 2025 //
GLOBENEWSWIRE
Fortress Biotech Reports 2024 Financial Results and Highlights
31 Mar 2025 //
GLOBENEWSWIRE
Partex & Fortress Bio Collaborate to Accelerate Asset Identification
17 Mar 2025 //
GLOBENEWSWIRE
Fortress Biotech Doses First Patient In Phase 2 Triplex Trial
27 Jan 2025 //
GLOBENEWSWIRE
FDA Accepts Fortress-Cyprium NDA For Menkes Disease Treatment
06 Jan 2025 //
GLOBENEWSWIRE
Fortress Biotech Reports Q3 2024 Financial Results & Corporate
14 Nov 2024 //
GLOBENEWSWIRE
Fortress Biotech To Participate In October 2024 Conferences
26 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech Prices $8M Offering
20 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Fortress Biotech Reduces Debt, Gets 35M Loan From Oaktree
25 Jul 2024 //
GLOBENEWSWIRE
Fortress Biotech To Participate In AGP Healthcare Showcase
16 May 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports Q1 2024 Results, Corporate Highlights
15 May 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
28 Mar 2024 //
GLOBENEWSWIRE
Fortress Biotech to Participate in 36th Annual ROTH Conference
12 Mar 2024 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering
03 Jan 2024 //
GLOBENEWSWIRE
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering
29 Dec 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of $10.0 Million Public Offering
14 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
10 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Launch of Proposed Public Offering
09 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Reverse Stock Split
09 Oct 2023 //
GLOBENEWSWIRE
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
05 Oct 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports 1Q 2023 FYR Results and Recent Corporate Highlights
15 May 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Record 2022 Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Two March 2023 Investor Conferences
07 Mar 2023 //
GLOBENEWSWIRE
